GenNext Technologies awarded second US patent for protein footprinting
GenNext Technologies, a growth-stage company providing instrumentation, software, and services, has earned a second patent protecting the company’s novel radical dosimetry technology which vastly improves the utility of protein footprinting for the study of biopharma-ceutical structure, function, and safety.
The United States Patent and Trademark Office issued the ‘Radical Dosimetry for the Analysis of Biopharmaceuticals and Biological Molecules’ patent, which protects the company’s novel core technology and Intellectual Property that enables real-time assessment of protein footprinting chemical reactions with robust accuracy and reproduci-bility, while substantially improving ease-of-use. Specifically, this patent protects GenNext’s novel approach to determining protein tertiary and quaternary structure, along with associated conformation, of a given biomolecule. This insight enables researchers to develop superior biosimilars and biotherapeutics that limit or eliminate adverse drug reactions while increasing the drug’s efficacy.
GenNext says their mission is to help researchers elucidate, through protein footprinting, the critical role that Higher Order Structure (HOS) plays in the safety, stability, and function of biotherapeutics. Although protein footprinting promised to revolutionize drug discovery, adoption has been slow due to the inherent complexity, dangerous instrumentation, and reproducibility challenges of older methods.
“With the launch of our Flash Oxidation System and Services in 2019, we solved these adoption problems by increasing the sensitivity, reproducibility, and ease-of-use of protein footprinting,” said Scot R. Weinberger, Founder and CEO of GenNext. “Now that a full-solution HOS technology platform and service is available to the structural biology research community, we’ve seen a surging adoption of this powerful technique by leading US and EU biopharmaceutical companies. We’re delighted to receive our second US patent as validation of our leadership in commercializing novel and robust protein footprinting technology.”
